Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial

(2020) Kamal Hamed et al.   Future Microbiology

Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia

(2020) Steven Y. C. Tong et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections — United States

(2019) Athena P. Kourtis et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Clinical Data on Daptomycin Plus Ceftaroline Versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

(2019) Matthew Geriak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftobiprole for the treatment of infective endocarditis: a case series

(2019) Carlo Tascini et al.   Journal of Global Antimicrobial Resistance

Impact of Vancomycin MIC on Clinical Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin at an Institution with Suppressed MIC Reporting

(2018) Shaili Adani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftobiprole medocaril for the treatment of community-acquired pneumonia

(2018) Vicenç Falcó et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016

(2018) Michael A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia

(2016) Sanjiv M. Baxi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections

(2015) S. Hal et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Daptomycin in Combination With Other Antibiotics for the Treatment of Complicated Methicillin-Resistant Staphylococcus aureus Bacteremia

(2014) Abhay Dhand et al.   CLINICAL THERAPEUTICS

Association Between Vancomycin Minimum Inhibitory Concentration and Mortality Among Patients WithStaphylococcus aureusBloodstream Infections

(2014) Andre C. Kalil et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis

(2012) S. J. van Hal et al.   CLINICAL INFECTIOUS DISEASES

Characteristics and Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections in Patients with Cancer Treated with Vancomycin: 9-Year Experience at a Comprehensive Cancer Center

(2012) S. N. Mahajan et al.   ONCOLOGIST

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children

(2011) Catherine Liu et al.   CLINICAL INFECTIOUS DISEASES

Ceftobiprole Is Superior to Vancomycin, Daptomycin, and Linezolid for Treatment of Experimental Endocarditis in Rabbits Caused by Methicillin-Resistant Staphylococcus aureus

(2009) P. Tattevin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

(2007) A. Soriano et al.   CLINICAL INFECTIOUS DISEASES